



January 29, 2021

Company: KYORIN Holdings, Inc  
Representative: Yutaka Ogihara  
Representative Director, President  
(Securities Code: 4569, TSE 1st Sec.)  
Contact: Yoshinori Tanifuji  
Director, Corporate Planning  
Telephone: 03-3525-4707

### Release of four research reagents for Microfluidic Real-Time PCR System GeneSoC®

KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and CEO: Shigeru Ogihara; “KYORIN Pharmaceutical”), a subsidiary of KYORIN Holdings, Inc., released four research agents for respiratory tract infections using the microfluidic Real-Time PCR System “GeneSoC®” (“GeneSoC®”) today.

Each agent can detect multiple target genes in a sample simultaneously in a short time (about 15 minutes) using "GeneSoC®", and can be used according to each research use purpose.

KYORIN Pharmaceutical will continue to make further contributions to enhance the testing system and establish rapid testing methods such as shorten PCR test turnaround times for infectious diseases including the new coronavirus.

The impact of the release of these products on KYORIN Holdings’ consolidated operating results for the fiscal year ending March 31, 2021 is minor.

#### Product Summary

■ **Streptococcus pneumoniae / Haemophilus influenzae detection kit**

Supply price : 54,000 yen (plus tax) Packaging unit : 40 tests Storage temperature : -20°C

■ **Mycoplasma pneumoniae / Bordetella pertussis detection kit**

Supply price : 54,000 yen (plus tax) Packaging unit : 40 tests Storage temperature : -20°C

■ **MRSA detection kit**

Supply price : 54,000 yen (plus tax) Packaging unit : 40 tests Storage temperature : -20°C

■ **Influenza virus A / B / A group β-hemolytic streptococcus detection kit**

Supply price : 56,500 yen (plus tax) Packaging unit : 40 tests Storage temperature : -20°C